July 29, 2020

Research Reveals Potential Drug Target for Treating Obesity and Other Metabolic Conditions

Preclinical models focus interest on the protein hepsin

Brown Adipose

Researchers from the Department of Cardiovascular & Metabolic Sciences in Cleveland Clinic’s Lerner Research Institute have identified a new drug target that may help treat or prevent diabetes, dyslipidemia and obesity.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Findings from the study — led by Qingyu Wu, MD, PhD, and published in Proceedings of the National Academy of Sciences— show that the protein hepsin is an important regulator of metabolism and energy homeostasis, and inhibiting its expression may reduce the risk and severity of these metabolic disorders.

It’s long been recognized that hepsin is a transmembrane protein expressed primarily in liver tissue, as well as adipose tissue. To date, the physiological function and role of hepsin in disease had not been well defined.

Preventing hepsin expression has positive effect on several indicators of disease

To understand hepsin’s potential role in disease, Dr. Wu and his team studied mouse models engineered to be hepsin-deficient. Compared to hepsin-expressing mice, those with hepsin deficiency had lower glycogen and lipid levels and increased metabolic rates and adipose tissue browning (see image at top).


“Fat tissue can either be white or brown,” explains Dr. Wu. “Too much white adipose tissue can negatively affect a patient’s metabolism and risk for related disorders. Research suggests, though, that adipose tissue browning can reverse the negative effects of white adipose tissue and actually confer metabolic benefits.”

Importantly, the researchers also saw that healthy-weight hepsin-deficient mice were resistant to developing obesity, hyperglycemia and hyperlipidemia when fed a high-fight diet. Additionally, preventing hepsin expression in mice that were already obese and diabetic actually reduced the severity of those conditions over time.

Potential benefits of a drug for obesity

The researchers also conducted protein expression analyses to understand the downstream effects of hepsin deficiency. On a mechanistic level, hepsin deficiency caused reduced expression of hepatocyte growth factor (HGF) and impaired signaling between HGF and its receptor, Met.


Although more research is necessary, these early results suggest that hepsin (through the hepsin/HGF-Met signaling cascade) increases glycogen and lipid production in the liver and lowers metabolic rates and adipose tissue browning. Targeting and inhibiting its activity may help treat a host of metabolic disorders.

“Given the prevalence of metabolic disorders, including obesity and diabetes, identifying a drug target to not only treat but also prevent, these conditions would have profound patient and economic benefit,” says Dr. Wu. “We believe our study offers compelling evidence that hepsin may be a viable option.”

Related Articles

Diabetes and pregnancy
November 8, 2023
New Programs Support the Needs of Patients with Pregnancy and Diabetes

Maternal-fetal medicine specialists, endocrinologists and educators team up

Patient counseling
October 31, 2023
Transitioning from Pediatric to Adult Care for Obesity

Giving young patients a hand as they take charge of their own health

Pregnant woman on couch
October 27, 2023
When Hypertension in Pregnancy Signals Something Else

Case illustrates how easily condition can mimic preeclampsia

giant prolactinoma
October 3, 2023
Surgical Management of Giant Prolactinomas

Analysis examines surgical resection of rare pituitary tumors

chronic kidney disease
September 1, 2023
Improving Management of Diabetes and Chronic Kidney Disease

Screening and medication key to better outcomes

diabetic neuropathy
August 30, 2023
Significant Relief for Some With Diabetic Neuropathy

Spinal cord stimulation can help those who are optimized for success

August 10, 2023
Endocrinopathies from Checkpoint Inhibitors

Incidence, outcomes and management

illustration of LDL cholesterol particle
June 26, 2023
CLEAR Outcomes Subanalysis Shows Strong Primary Prevention Effect for Bempedoic Acid

Robust reductions in cardiac events seen in high-risk patients without prior events